// App-Quantinova.ai

: Impact of Baseline Blood Eosinophil Count on Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Researchers

Presenter

  • Marc Rothenberg

Principal Investigators

  • Florence Roufosse

  • Stanislas Faguer

  • Gerald Gleich

  • Jean-Emmanuel Kahn

  • Jonathan Steinfeld

  • Namhee Kwon

  • Jane Bentley

  • Steve Yancey

Medical Centers

  • Cincinnati Childrens Hospital Medical Center and University of Cincinnati, Cincinnati, OH

  • Hopital Erasme- universite Libre de Bruxelles, Brussels, Belgium

  • Centre de Référence des Maladies Rénales Rares, Hôpital Rangueil, CHU de Toulouse, Toulouse, France

  • Internal Medicine, University of Utah, Salt Lake City, UT

  • Hopital Ambroise Pare, Universite de Versailles St Quentin en Yvelines, Boulogne Billancourt, France

  • GSK, Collegeville, PA

  • GSK, Brentford, London, UK

  • GSK, Stockley Park, Uxbridge, Middlesex, UK

  • GSK, Research Triangle Park, NC, USA

Locations

  • United States

  • Belgium

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Hypereosinophilic Syndrome

Biomarkers

  • Eosinophil

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved